Daiichi Sankyo to end agreement with Charleston Laboratories for hydrocodone products

Daiichi Sankyo has elected to terminate its existing agreement with Charleston Laboratories to forgo the development and commercialisation of hydrocodone products in the US for the treatment of moderate-to-severe acute pain and to reduce opioid-induc …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news